159 related articles for article (PubMed ID: 19372566)
1. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
VanderPorten EC; Taverna P; Hogan JN; Ballinger MD; Flanagan WM; Fucini RV
Mol Cancer Ther; 2009 Apr; 8(4):930-9. PubMed ID: 19372566
[TBL] [Abstract][Full Text] [Related]
2. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
3. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
[TBL] [Abstract][Full Text] [Related]
4. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
5. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Kaestner P; Stolz A; Bastians H
Mol Cancer Ther; 2009 Jul; 8(7):2046-56. PubMed ID: 19584233
[TBL] [Abstract][Full Text] [Related]
6. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
7. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent and selective aurora kinase inhibitor.
Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
[TBL] [Abstract][Full Text] [Related]
9. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
Dowling M; Voong KR; Kim M; Keutmann MK; Harris E; Kao GD
Cancer Biol Ther; 2005 Feb; 4(2):197-206. PubMed ID: 15753652
[TBL] [Abstract][Full Text] [Related]
10. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
11. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
[TBL] [Abstract][Full Text] [Related]
12. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
[TBL] [Abstract][Full Text] [Related]
13. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
[TBL] [Abstract][Full Text] [Related]
14. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents.
Wysong DR; Chakravarty A; Hoar K; Ecsedy JA
Cell Cycle; 2009 Mar; 8(6):876-88. PubMed ID: 19221504
[TBL] [Abstract][Full Text] [Related]
16. A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor.
DeMoe JH; Santaguida S; Daum JR; Musacchio A; Gorbsky GJ
Cancer Res; 2009 Feb; 69(4):1509-16. PubMed ID: 19190331
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
18. A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint.
Mistry HB; MacCallum DE; Jackson RC; Chaplain MA; Davidson FA
Front Biosci (Landmark Ed); 2010 Jan; 15(1):249-58. PubMed ID: 20036819
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.
Skobeleva N; Menon S; Weber L; Golemis EA; Khazak V
Mol Cancer Ther; 2007 Mar; 6(3):898-906. PubMed ID: 17363484
[TBL] [Abstract][Full Text] [Related]
20. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
